MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today ...

U.S.-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences have launched a new company armed ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars ...

Thanks to an innovative method of super-resolution microscopy, researchers from the University of Würzburg have observed ...

Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced that it has dosed the first patient in its CELESTIAL-301 Phase 1 clinical trial. The ...

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer ...

Würzburg researchers show in the journal 'Science' how therapeutic antibodies work - thanks to an innovative method of ...

Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...

By advancing next-generation AI/DL-based pathology analysis platforms and promoting the use of the newly developed ...

Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H’25 - - IND application for CRG-023, CARGO’s tri-specific CAR T, cleared by the FDA ...

Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based ...

NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to ...